Dolutegravir/lamivudine/tenofovir alafenamide

Dolutegravir/lamivudine/tenofovir alafenamide is a fixed-dose combination of antiretroviral drugs used in the treatment of HIV/AIDS. This combination is marketed under the brand name Dovato by ViiV Healthcare, a specialist HIV company majority owned by GlaxoSmithKline.

Composition

The combination consists of three active ingredients:

• Dolutegravir, an integrase inhibitor that prevents the virus from integrating its genetic material into the host cell.
• Lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI) that blocks a key enzyme, reverse transcriptase, which the virus needs to reproduce.
• Tenofovir alafenamide, another NRTI that works in a similar way to lamivudine.

Usage

Dolutegravir/lamivudine/tenofovir alafenamide is used as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of this drug.

Side Effects

Common side effects include headache, diarrhea, nausea, fatigue and insomnia. Serious side effects may include liver problems, kidney problems, lactic acidosis, severe skin rash and allergic reactions.

See Also

• Antiretroviral therapy
• HIV/AIDS
• ViiV Healthcare
• GlaxoSmithKline